Medical Management of Dysfunctional Menorrhagia: Is Ormeloxifene a Safe and Efficacious Therapeutic Choice?

Nidhi Gupta

ABSTRACT

Objective: To assess the efficacy and safety of ormeloxifene (centchroman) in the medical management of menorrhagia.

Materials and methods: One hundred and twenty women with menorrhagia were recruited for the study. One hundred women were analyzed. Ormeloxifene was given to each patient—60 mg twice a week for 3 months and then once a week for 1 month. Patients were followed up at 2, 4, 6 months of therapy, then at 6 months after treatment was stopped. Menstrual blood loss (MBL) was measured objectively by a pictorial blood loss assessment chart (PBAC) score and subjectively by a visual analog scale (VAS).

Results: The mean age of the patients was 38.2 years with a mean parity of 2.4. The mean duration of menorrhagia was 13 months with 8 days as mean duration of bleeding and a mean cycle length of 26 days. 58.7% of the patients had bulky uterus on per vaginum examination done by the same observer. The mean endometrial thickness on transvaginal scan was 8.7 mm. The different study parameters were evaluated in patients treated with ormeloxifene and it showed a significant reduction in median PBAC score from 252 to 102.8, presence of clots from 64 to 12%, incidence of dysmenorrhea from 22 to 8% and mean endometrial thickness from 9.7 to 6.7 mm. There was also a significant elevation in the mean hemoglobin levels from 8.85 gm/dl to 10.8 gm/dl.

The menstrual pattern of patients treated with ormeloxifene were encouraging. Eight percent of the women became amenorrheic after 6 months of therapy, 22% had scanty period, 8% and mean endometrial thickness from 9.7 to 6.7 mm. There was also a significant elevation in the mean hemoglobin levels from 8.85 gm/dl to 10.8 gm/dl.

It was further seen, that even though the PBAC score increased to 112.7 after stopping treatment for 6 months, but still it was lower than the pretreatment level (252). The percentage of patients who had an initial history of passage of clots during periods decreased from 64 to 12% and also 22% of patients who complained of mild to severe dysmenorrhea improved and only 8% of the patients complained of mild dysmenorrhea.

Adverse effects: Included ovarian cyst (14%), cervical erosion and discharge (11%), gastric upset (9%), headache (5%) and weight gain (3%).

Conclusion: Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia.

Keywords: Centchroman, Menorrhagia, Ormeloxifene.

How to cite this article: Gupta N. Medical Management of Dysfunctional Menorrhagia: Is Ormeloxifene a Safe and Efficacious Therapeutic Choice? J South Asian Feder Menopause Soc 2014;2(2):65-70.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Menorrhagia is a common cause of disability affecting about 10 to 33% of women at some stage in their lives.1 In majority of cases, no organic disease can be attributed to this condition and then it is termed as dysfunctional or essential menorrhagia.

Menorrhagia is usually defined as menstrual blood loss of at least 80 ml or more per cycle2 and on a pictorial blood loss assessment chart (PBAC) score of more than 100.3

Although, the definitive treatment of dysfunctional menorrhagia is hysterectomy, but this involves hospitalization, anesthesia, morbidity, loss of fertility and it may not be the preferred choice in all women. Dysfunctional menorrhagia is usually seen in premenopausal women in whom the condition usually rectifies with the onset of menopause.4

Although, endometrial ablative procedures, an alternative to hysterectomy, may show promising results but their use is limited especially in low resource settings like ours. The cost, a long learning curve, high recurrence rates and the absence of cost-effective, easy and universal availability of the first and second generation procedures limits their use.5

Drug therapy should therefore, be the first line of treatment in all cases of dysfunctional menorrhagia before recourse to surgery.6 Although, a large number of drugs7,8 have shown promising results but still it is seen that many women remain menorrhagic despite a 50% decrease in mean blood loss by agents like tranexamic acid, mfenamic acid, flurbiprofen, norethisterone and ethamsylate. Secondly, there is paucity of recommendations to guide its systematic implementation and lastly long-term daily oral drug treatment has restricted usage due to poor compliance and unacceptable side effects. Though, the use of the Levonorgestrel intrauterine system
Selective estrogen receptor modulators (SERMs) represent a novel therapeutic drug class in the medical management of menorrhagia. Their actions are dichotomously defined at the molecular level; pharmacologic actions are composite of estrogen agonistic and antagonistic effects. The cardinal features of SERMs that are useful is their high affinity to bind to nuclear estrogen receptors, causing antagonistic estrogen effects in the uterus and breast tissue and estrogen mimicking actions on the skeletal, cardiovascular and central nervous systems.\textsuperscript{10}

Ormeloxifene is a nonsteroidal SERM developed as centchroman by Indian Central Drug Research Institute, Lucknow, India\textsuperscript{11} and used as a weekly oral contraceptive for around 20 years. During this usage, it was observed in India that this drug has a beneficial effect on dysfunctional uterine bleeding and endometriosis. This led to controlled trials of this drug for this indication. It is also undergoing clinical evaluation for treatment of breast diseases (mastalgia, fibroadenoma, breast carcinoma) and prevention of osteoporosis due to its potent anti-estrogenic, weak estrogenic\textsuperscript{12,13} and antiprogestational activities.\textsuperscript{14}

**MATERIALS AND METHODS**

After ethical approval was obtained, the study was conducted at the department of Obstetrics and Gynecology, Malhotra Nursing Home and Rainbow Hospital, Pvt Ltd, Agra, India and the effect of Ormeloxifene was studied in cases of dysfunctional menorrhagia.

Two hundred patients with menorrhagia (between January 2010 and January 2014) were randomly selected from the outdoor department of the obstetrics and gynecology of the above hospitals for the study. Fifty were excluded as they failed to fulfill the inclusion criteria and 50 were lost to follow-up and 100 were analyzed. They were clinically evaluated with a detailed menstrual history pertaining to cycle length and duration of bleeding. PBAC score and visual analog scale (VAS) was used for assessment of passage of clots and dysmenorrhea.

Patients, whose menstrual blood loss on the PBAC scored more than 100 were recruited.

Hemograms were performed as well as ultrasonography was done to rule out pelvic pathology and to measure the endometrial thickness.

Endometrial biopsy was done for all patients.

Exclusion criteria included presence of any pelvic or systemic pathology (e.g. platelet disorder, coagulopathies, previous h/o thrombosis, renal or hepatic dysfunction), pregnancy, associated infertility and endometrial hyperplasia with atypia. Endocrinopathy or other systemic diseases causing menorrhagia were also excluded from the study.

The women were preferably multipara, who did not wish to conceive within the study period and had no clinical evidence of jaundice or hepatic dysfunction, polycystic ovarian disease, cervical hyperplasia, chronic cervicitis and hypersensitivity to the drug.

Informed written consent was taken from all the patients.

Two pretreatment menstrual cycles were studied and then compared to six consecutive treatment cycles with ormeloxifene. The drug was administered orally in the form of a tablet 60 mg twice a week for the first 12 weeks and then once a week for another 12 weeks.

Follow-ups were done at 2, 4, 6 months of therapy to assess improvement of symptoms. After the therapy was stopped, each patient was followed-up for a period of 6 months. Thus, the total duration of the study was 12 months.

The main outcome measures were menstrual blood loss, blood hemoglobin levels and endometrial thickness in the proliferative phase as studied by transvaginal sonography (TVS).

The patients were asked to keep records of their menstrual patterns, bleeding days and amount of menstrual blood loss. They were also advised to bring the empty packets of drugs used by them. Follow-up was done at 2, 4 and 6 months of therapy and then 6 months after stopping the therapy. At each visit, cycle length, duration of bleeding, PBAC score any side effect and patients subjective account of bleeding and dysmenorrhea was assessed by VAS.

Amenorrhea was defined as absence of menstruation for two consecutive cycles. Patients with a PBAC score of \(<\) 10 was defined as scant flow; between 10 and 100 as moderate flow; \(>\) 100 as heavy flow and \(>\) 300 as very heavy flow.

No hormone, antifibrinolytics or any other agent to control menorrhagia was prescribed during the study.

A repeat endometrial biopsy was performed in all patients if on TVS endometrial thickness was \(>\) 10 mm.

If menorrhagia was controlled over 4 cycles of treatment, the treatment was considered a success. Women who developed the same symptoms of dysfunctional menorrhagia in the follow-up period and who requested repeat treatment with ormeloxifene were recorded as represcription cases and started treatment.

Pictorial blood loss assessment chart (PBAC), a method that correlates well, with the alkaline test method\textsuperscript{15} was used to measure the menstrual blood loss. A well designed questionnaire recorded the subjective assessment of
Menstrual flow and dysmenorrhea and any side effects of the drug. Menstrual flow was designated as light, normal or average, heavy and flooding. Number and size of clots passed were also noted. Dysmenorrhea was categorized as absent, mild, moderate and severe.

RESULTS
A total of 200 women (Flow Chart 1) with menorrhagia (PBAC Score > 100) were screened and out of which 50 cases were excluded due to presence of systemic or pathological disease (Flow Chart 1).

One hundred and fifty were enrolled for the study and informed consent was taken but 30 women were lost to follow-up and only 120 women were analyzed and started therapy.

Out of the 120 women only 110 women continued therapy after the 1st follow-up (2 months after therapy) and 4 of these had poor response and opted for other forms of medical therapy, 4 underwent hysterectomy and 2 were lost to follow-up.

In the next follow-up after 4 months, two women opted out of the study due to poor response and underwent hysterectomy. Only 100 patients reported for the 3rd follow-up after 6 months of therapy six patients were lost to follow-up and two showed poor response with therapy.

The number of patients reporting 3 and 6 months after stopping therapy were 98 and 96 respectively (two in each group were lost to follow-up). Ours is a tertiary teaching hospital catering to a wide population from the neighboring districts and the patients who were lost to follow-up were mainly the rural dwellers in the low socio-economic group, who did not report even on contacting and counseling them telephonically.

Table 1 delineates the patient characteristics treated with ormeloxifene. The mean age of the patients was 38.2 years with a mean parity of 2.4. The mean duration of menorrhagia was 13 months with 8 days as mean duration of bleeding and a mean cycle length of 26 days. 58.7% of the patients had bulky uterus on per vaginum examination done by the same observer. The mean endometrial thickness on transvaginal scan was 8.7 mm. An endometrial aspiration was done in all patients and endometrium was sent for histopathological evaluation (Table 2). The endometrium was secretory in 52%, proliferative in 33.4%, simple hyperplasia without atypia in 9.8%, cystic hyperplasia without atypia in 3.6% and with atypia in 1.2% (Table 2). The patient with endometrial hyperplasia with atypia was referred for hysterectomy.

As regards the adverse effects (Table 3) of the drug, 58% reported no side-effects, in fact eight patients who had mastalgia benefited from the treatment. 11.8% of cases complained of severe abdominal pain and on ultrasonography had ovarian cyst which were simple follicular in type with a mean diameter of 6.7 cm. Most of the cysts were simple follicular and benign which disappeared within 3 months of stopping therapy (one of the patient showed a complex cyst with a diameter of 9.8 cm but, later it was confirmed to be a hemorrhagic cyst).

### Table 1: Patient characteristics

<table>
<thead>
<tr>
<th>S no.</th>
<th>Patient characteristics</th>
<th>Mean score</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Age</td>
<td>38.2 years</td>
<td>27-51 years</td>
</tr>
<tr>
<td>2</td>
<td>Parity</td>
<td>2.4</td>
<td>0-5</td>
</tr>
<tr>
<td>3</td>
<td>Duration of menorrhagia</td>
<td>13 months</td>
<td>4-56 months</td>
</tr>
<tr>
<td>4</td>
<td>Duration of bleeding days</td>
<td>8 days</td>
<td>4-30 days</td>
</tr>
<tr>
<td>5</td>
<td>Cycle length</td>
<td>26 days</td>
<td>16-30 days</td>
</tr>
<tr>
<td>6</td>
<td>Size of uterus on P/V examination done by same observer.</td>
<td>41.3%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– Normal size</td>
<td>58.7%</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Endometrial thickness by TVS</td>
<td>8.7 mm</td>
<td>5-15 mm</td>
</tr>
</tbody>
</table>

### Table 2: Histopathological evaluation of endometrial thickness of all patients enrolled in the study

<table>
<thead>
<tr>
<th>S no.</th>
<th>Histopathological evaluation of endometrial aspiration</th>
<th>Number (out of 150)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Secretory endometrium</td>
<td>78/150</td>
<td>52.0</td>
</tr>
<tr>
<td>2</td>
<td>Proliferative endometrium</td>
<td>50/150</td>
<td>33.4</td>
</tr>
<tr>
<td>3</td>
<td>Simple hyperplasia without atypia</td>
<td>14/150</td>
<td>9.8</td>
</tr>
<tr>
<td>4</td>
<td>Cystic hyperplasia without atypia</td>
<td>06/150</td>
<td>3.8</td>
</tr>
<tr>
<td>5</td>
<td>Cystic hyperplasia with atypia</td>
<td>02/150</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Flow Chart 1: A disposition tree showing the number of patients screened, enrolled, analyzed and lost the follow-up in the study of ormeloxifene in management of menorrhagia.

No. of patients screened (200) → Excluded (50) → No. of patients enrolled (150) → No. of patients analyzed (120) → No. of patients completing 1st FUP, 2nd FUP and 3rd FUP (100) → No. of patients reporting after 3 months post-treatment (96) → No. of patients reporting after 6 months post-treatment (96)
Out of 9.2% of the patients in the study reported vaginal discharge which was excessive and per speculum examination of these cases revealed that they had cervical erosion. All these patients underwent a Pap smear and a colposcopic directed biopsy whenever it was required. Gastric upset in the form of nausea, bloating and belching was seen in 7.1% cases and 6.2% of the cases reported vague and nonspecific low abdominal pain and these were relieved by medication and change of diet. 4.8% of cases reported headache and 2.9% reported weight gain (2.5 kg in 12 months).

The different study parameters were evaluated in patients treated with ormeloxifene (Table 4) and it showed a significant reduction in median PBAC score from 252 to 102.8, presence of clots from 64 to 12%, incidence of dysmenorrhea from 22 to 8% and mean endometrial thickness from 9.7 to 6.7 mm. There was also a significant elevation in the mean hemoglobin levels from 8.85 to 10.6 gm/dl.

The menstrual pattern of patients (Table 5)treated with ormeloxifene were encouraging. 8% of the women became amenorrhoeic after 6 months of therapy, 22% had scanty period, 56% had average flow, 12% had heavy flow and only 2% had very heavy flow.

Out of 8% of patients with amenorrhea only two cases continued to be amenorrhoeic even after stopping therapy (4th follow-up) and the rest resumed their menses within 3 to 6 months of stopping therapy. These patients were in the 48 to 51 years age group and the amenorrhea was welcomed by them.

| Table 3: Adverse effects seen with ormeloxifene reported by the patients |
|---|---|---|
| S no. | Side-effect | Number (Out of 100) | Percentage |
| 1 | No side-effects reported | 58/100 | 58 |
| 2 | Severe abdominal pain (ovarian cyst on USG) | 14/100 | 14 |
| 3 | Discharge (cervical erosion on p/s examination) | 11/100 | 11 |
| 4 | Gastric upset | 09/100 | 9 |
| 5 | Headache | 05/100 | 5 |
| 6 | Weight gain | 03/100 | 3 |

It was observed that, 12 patients had recurrence of symptoms after 6 months of stopping the therapy. Surprisingly, 5 patients opted for the same medical treatment, that is ormeloxifene and 2 each opted for other forms of medical management and hysterectomy.

It was seen, that even though the PBAC score increased to 112.7 after stopping treatment for 6 months, but still it was lower than the pretreatment level (252). The percentage of patients who had an initial history of passage of clots during periods decreased from 64 to 12% and also 22% of patients who complained of mild to severe dysemenorrhea improved and only 8% of the patients complained of mild dysmenorrhea.

**DISCUSSION**

Medical management for dysfunctional menorrhagia should aim to relieve symptoms of menorrhagia, improve the quality of life and avoid risk of hysterectomy. It should be safe, easy to administer with minimal side effects and the therapeutic advantage should also continue even after stopping the therapy. Till date, no such drug has been marketed and the drugs available seems to provide only partial relief from menorrhagia.16

Ormeloxifene, a new drug, added to this medical armamentarium has a long lasting estrogen antagonistic action and lately studies are showing it to be a safe and effective therapeutic option in the management of dysfunctional uterine bleeding. Secondly, due to a long half life elimination doses provide for easy and convenient biweekly and then after building adequate and effective blood levels of the drug shifting to weekly doses. Thirdly, its effect is local, with no effect on the hypothalmopituitary axis, so it does not affect ovulation. It causes an increase in cycle length by lengthening the follicular phase.


### Table 6: Comparative analysis in different parameters of treatment of dysfunctional menorrhagia with ormeloxifene conducted by different Indian workers

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Median PBAC score</td>
<td>272</td>
<td>107.8</td>
<td>388</td>
<td>96</td>
<td>108.7</td>
<td>62.48</td>
<td>252</td>
<td>102.8</td>
</tr>
<tr>
<td>2</td>
<td>Mean hemoglobin level (gm/dl)</td>
<td>9.42</td>
<td>10.73</td>
<td>10.6</td>
<td>11.2</td>
<td>8.49</td>
<td>11.028</td>
<td>8.85</td>
<td>10.6</td>
</tr>
<tr>
<td>3</td>
<td>Mean endometrial thickness (mm)</td>
<td>11.4</td>
<td>7.8</td>
<td>10.9</td>
<td>7.3</td>
<td>11.5</td>
<td>8</td>
<td>8.7</td>
<td>6.7</td>
</tr>
<tr>
<td>4</td>
<td>Presence of clots (%)</td>
<td>74.1</td>
<td>12.9</td>
<td>64.3</td>
<td>7.1</td>
<td>80</td>
<td>8</td>
<td>64</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>Presence of dysmenorrhea (%)</td>
<td>27.05</td>
<td>5.88</td>
<td>71.4</td>
<td>25</td>
<td>—</td>
<td>—</td>
<td>22</td>
<td>8</td>
</tr>
</tbody>
</table>

The mean blood loss decreased significantly in our study which is in concordance with other studies with medical management18 though less than with the LNG-IUS system19 (Table 6). It was further observed that 8% of women became amenorrheic with 22% of women having scanty menses and 56% of women had a average menstrual blood flow. So, it was observed that in 86% of women menorrhagia was cured. Similar results were such by the study conducted by Kriplani et al,20 in whom menorrhagia was cured in 78% of patients, 46% patients had amenorrhea and 32% had regular scant to moderate menstrual blood loss. Similar, results were seen by study conducted by Chandra et al21 where there was an improvement of menorrhagia in 85.7% of cases and amenorrhea was observed in 17.64% of the cases. Similar results were also shown by the study conducted by Tapan et al.22

Ormeloxifene has got a good safety profile with very few side effects. In our study, none of the side-effects were severe enough to stop therapy. 11.8% of patients reported severe abdominal pain and were found to have simple follicular cysts on transvaginal scan. This was comparable to the incidence of ovarian cysts seen in other studies, Rajan et al23 (15%) and Kriplani et al (7.1%). These cysts are usually follicular and disappeared in subsequent cycles. 9.2% of the patients complained of vaginal discharge and were found to have cervical erosion on per-speculum examination and acute on chronic inflammation on Pap smear, which were treated accordingly.

### CONCLUSION

Ormeloxifene decreases mean blood loss significantly in the first two cycles itself. The effect does not plateau, rather further reduction is seen in the subsequent cycles. This reduction in menstrual blood loss is greater than that, achieved by other oral medication.

To facilitate the drugs steady state concentration in plasma a twice weekly loading dose in the beginning of therapy is to be considered for the first 3 months and then a step down to a weekly dosing schedule gives a better compliance and decreases the relapse cases.

Action of ormeloxifene is local and has no effect on the hypothalmopituitary axis so the drug has a good safety profile and can be safely used in pre and perimenopausal women on a long-term bases without any significant adverse effects.

It is a good drug for perimenopausal women especially in women in whom steroidal treatment is either not recommended or not desired. Orlmexifene is an effective, safe and a well-tolerated option for the management of dysfunctional menorrhagia.
REFERENCES


